What do systematic reviews say?

Sulthiame vs phenytoin

Sulthiame showed no clear difference in all adverse effects compared with phenytoin (low certainty).

• Sulthiame monotherapy for epilepsy 2021 · Cochrane Headline outcomes only
  RR 1.05 [0.54, 2.07]
  1 study · 146 participants
  Low

Sulthiame vs placebo

• Sulthiame monotherapy for epilepsy 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 100 participants
  GRADE not reported

Sulthiame vs levetiracetam

Sulthiame showed no clear difference in adverse effects (others) compared with levetiracetam (low certainty).

• Sulthiame monotherapy for epilepsy 2021 · Cochrane Headline outcomes only
  RR 1.19 [0.37, 3.85]
  1 study · 43 participants
  Low

Sulthiame vs levetiracetam

Sulthiame showed no clear difference in adverse effects (cardiac) compared with levetiracetam (low certainty).

• Sulthiame monotherapy for epilepsy 2021 · Cochrane Headline outcomes only
  RR 2.87 [0.12, 66.75]
  1 study · 43 participants
  Low

Sulthiame vs levetiracetam

Sulthiame may leads to higher adverse effects (airways) compared with levetiracetam (low certainty).

• Sulthiame monotherapy for epilepsy 2021 · Cochrane Headline outcomes only
  RR 2.67 [1.17, 6.12]
  1 study · 43 participants
  Low

Sulthiame vs levetiracetam

Sulthiame showed no clear difference in adverse effects (behaviour) compared with levetiracetam (low certainty).

• Sulthiame monotherapy for epilepsy 2021 · Cochrane Headline outcomes only
  RR 0.95 [0.59, 1.55]
  1 study · 43 participants
  Low

Sulthiame vs levetiracetam

Sulthiame showed no clear difference in adverse effects (gastrointestinal) compared with levetiracetam (low certainty).

• Sulthiame monotherapy for epilepsy 2021 · Cochrane Headline outcomes only
  RR 0.76 [0.37, 1.56]
  1 study · 43 participants
  Low

Sulthiame vs levetiracetam

Sulthiame showed no clear difference in adverse effects (general symptoms) compared with levetiracetam (low certainty).

• Sulthiame monotherapy for epilepsy 2021 · Cochrane Headline outcomes only
  RR 1.08 [0.76, 1.54]
  1 study · 43 participants
  Low

Sulthiame vs levetiracetam

Sulthiame showed no clear difference in adverse effects (bones and muscles) compared with levetiracetam (low certainty).

• Sulthiame monotherapy for epilepsy 2021 · Cochrane Headline outcomes only
  RR 0.95 [0.27, 3.33]
  1 study · 43 participants
  Low

Sulthiame vs levetiracetam

Sulthiame showed no clear difference in adverse effects (central nervous system) compared with levetiracetam (low certainty).

• Sulthiame monotherapy for epilepsy 2021 · Cochrane Headline outcomes only
  RR 1.17 [0.77, 1.79]
  1 study · 43 participants
  Low

Sulthiame add‐on vs placebo

It is very uncertain whether sulthiame add‐on changes adverse effects: somnolence compared with placebo (very low certainty).

• Sulthiame add‐on therapy for epilepsy 2019 · Cochrane Headline outcomes only
  RR 3.4 [0.42, 27.59]
  1 study · 37 participants
  Very low

Sulthiame add‐on vs placebo

It is very uncertain whether sulthiame add‐on changes adverse effects: total number of participants experiencing one or… compared with placebo (very low certainty).

• Sulthiame add‐on therapy for epilepsy 2019 · Cochrane Headline outcomes only
  RR 0.85 [0.44, 1.64]
  1 study · 37 participants
  Very low